Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856080 | 0.84 | PIK3CD (0.46) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL18542702 | 0.81 | PIK3CD (0.43) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL12156277 | 0.80 | PIK3CD (0.42) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL13617466 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2AKR1C3EPHX1HRH3 | |
| SCHEMBL12156690 | 0.78 | PIK3CD (0.41) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL14725147 | 0.77 | HRH3 (0.41) | CYP2D6ALDH1A1AKR1C3KCNH2HRH3 | |
| SCHEMBL13312886 | 0.77 | PIK3CD (0.55) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL25468422 | 0.76 | PIK3CD (0.38) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL13683795 | 0.76 | PIK3CD (0.44) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 | |
| SCHEMBL23842233 | 0.76 | PIK3CD (0.46) | PIK3CDCYP2D6KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885KDM4E 190/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885KDM4E 190/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885CYP2D6 3599/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.